Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN.
FILSPARI vs TELMISARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Angiotensin II receptor antagonist; selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
200 mg orally once daily, with or without food.
40 mg orally once daily; range 20-80 mg/day
None Documented
None Documented
Clinical Note
moderateTelmisartan + Benzydamine
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine."
Clinical Note
moderateTelmisartan + Droxicam
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam."
Clinical Note
moderateTelmisartan + Loxoprofen
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen."
Clinical Note
moderateTelmisartan + Clonixin
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Terminal half-life is approximately 24 hours (range 20–30 hours), supporting once-daily dosing without significant accumulation.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Primarily biliary-fecal (approximately 97% unchanged in feces); renal excretion accounts for <1% of the dose.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin."